Abstract
In testing novel anticancer therapies, researchers strive to utilize models that reflect the human disease as much as feasible. In this regard, orthotopic models are frequently developed because cancer cells in these models form tumors in, and metastasize from, a tissue environment similar to the tissue of origin of the cancer cells. Here we adapted an orthotopic colorectal cancer model, in which HT-29 colorectal cancer cells form tumors in the rectal lining and metastasize to the para-aortic lymph nodes with high frequency. Firefly luciferase-expressing HT-29 cells were used in this model to realize the benefits of bioluminescence imaging (BLI). A combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (LV) (IFL) was used as a standard chemotherapeutic regimen positive control. BLI allowed for the demonstration of the effects of IFL on tumor growth in the rectal lining, with tumor weight measurements at the end of the study reflecting total tumor burden. BLI also allowed relatively easy demonstration of reduced tissue metastasis with IFL treatment, compared to more time-consuming histological techniques. It is concluded that the orthotopic colorectal cancer model approach described represents a valuable tool for validating treatment strategies in this indication.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Fogh J., Orfeo T., Tiso J., Sharkey F.E., Fogh J.M., Daniels W.P. (1980) Twenty-three new human tumor lines established in nude mice. Exp Cell Biol 48, 229–239.
Morikawa K., Walker S.M., Nakajima M., Pathak S., Jessup J.M., Fidler I.J. (1988) Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res 48, 6863–6871.
Hoffman R.M. (1999) Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 17, 343–359.
Fidler I.J. (1995) Critical factors in the biology of human cancer metastasis. Am Surg 61, 1065–1066.
Hoffman R.M. (1994) Orthotopic is orthodox: why are orthotopic-transplant metastatic models different from all other models? J Cell Biochem 56, 1–3.
Kubota T. (1994) Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J Cell Biochem 56, 4–8.
Lo D.S., Pollett A., Siu L.L., Gallinger S., Burkes R.L. (2008) Prognostic significance of mesenteric nodules in patients with stage III colorectal cancer. Cancer 112, 50–4.
Wu Z.Y., Wan J., Li J.H., Zhao G., Yao Y, Du J.L., et al. (2007) Prognostic value of lateral lymph node metastasis for advanced low rectal cancer. World J Gastroenterol 13, 6048–6052.
Berger A.C., Sigurdson E.R., LeVoyer T., Hanlon A., Mayer R.J., Macdonald J.S., Catalano P.J., Haller D.G. (2005) Colon cancer survival associated with decreasing ratio of metastatic to examined lymph nodes. J Clin Oncol 23, 8706–8712.
Schumacher P., Dineen S., Barnett C., Fleming J., Anthony T. (2007) The metastatic lymph node ratio predicts survival in colon cancer. Am J Surg 194, 827–832.
Kashtan H., Rabau M., Mullen J.B.M., Wong A.H.C., Roder J.C., Shpitz B. (1992) Intra-rectal injection of tumor cells: a novel animal model of rectal cancer. Surg Oncol 1, 251–256.
Tsutsumi S., Kuwano H., Morinaga N., Shimura T., Aso T. (2001) Animal model of para-aortic lymph node metastasis. Cancer Lett 169, 77–85.
Jenkins D.E., Hornig Y.S., Oei Y., Dusich J., Purchio T. (2005) Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastasis in immune deficient mice. Breast Cancer Res 7, R444–R454.
Jenkins D.E., Yu S.-F., Hornig Y.S., Purchio T., Contag P.R. (2003) In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3 M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 20, 745–756.
Saltz L.B., Cox J.V., Blanke C., Rosen L.S., Fehrenbacher L., Moore M.J., Maroun J.A., Ackland S.P., Locker P.K., Pirotta N., Elfring G.L., Miller L.L. (2000) Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343, 905–914.
Acknowledgment
The authors would like to thank Jessica Kearney for her role in determining the Maximum Tolerated Dose (MTD) of IFL regimen in Nu/Nu mice.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Surguladze, D., Steiner, P., Prewett, M., Tonra, J.R. (2010). Methods for Evaluating Effects of an Irinotecan + 5-Fluorouracil/Leucovorin (IFL) Regimen in an Orthotopic Metastatic Colorectal Cancer Model Utilizing In Vivo Bioluminescence Imaging. In: Proetzel, G., Wiles, M. (eds) Mouse Models for Drug Discovery. Methods in Molecular Biology, vol 602. Humana Press. https://doi.org/10.1007/978-1-60761-058-8_14
Download citation
DOI: https://doi.org/10.1007/978-1-60761-058-8_14
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-60761-057-1
Online ISBN: 978-1-60761-058-8
eBook Packages: Springer Protocols